Market Research Logo

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2018

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2018'; Tyrosine Protein Kina


Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
LEO Pharma A/S
Nissan Chemical Industries Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
ABBV-599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abrocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-1777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-52793 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-54707 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIP-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peficitinib hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06700841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-0302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Jak1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
upadacitinib tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YJC-50018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2018: Incyte presents Itacitinib at the 60th Annual ASH meeting
Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting
Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting
Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease
Oct 23, 2018: AbbVie's Upadacitinib shows significant improvements in physical function, Pain and quality of life as a monotherapy in patients with Rheumatoid Arthritis in phase 3 patient-reported outcomes data
Oct 22, 2018: Positive trial results with Filgotinib in psoriatic arthritis and ankylosing spondylitis both published in The Lancet
Oct 22, 2018: Reistone Biopharma, a new Chinese biotech company ready to initiate its Ulcerative Colitis phase II clinical trial globally
Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018
Oct 22, 2018: Positive phase 2b data for AbbVie's Upadacitinib show significant induction of clinical remission and response in patients with Ulcerative Colitis
Oct 20, 2018: Phase 3 data on Filgotinib in biologic-experienced Rheumatoid Arthritis to be presented at 2018 ACR/ARHP Annual Meeting
Oct 16, 2018: AbbVie to present data on Upadacitinib at UEG Week 2018
Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting
Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Oct 08, 2018: AbbVie to provides update on Upadacitinib at the 2018 ACR/ARHP Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..4), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Products under Development by Companies, H2 2018 (Contd..7), H2 2018
Products under Development by Companies, H2 2018 (Contd..8), H2 2018
Products under Development by Companies, H2 2018 (Contd..9), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Aclaris Therapeutics Inc, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CJ HealthCare Corp, H2 2018
Pipeline by Concert Pharmaceuticals Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Galapagos NV, H2 2018
Pipeline by Han Wha Pharma Co Ltd, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Pipeline by LEO Pharma A/S, H2 2018
Pipeline by Nissan Chemical Industries Ltd, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Portola Pharmaceuticals Inc, H2 2018
Pipeline by Sareum Holdings Plc, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd..1), H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report